BRAF and cutaneous mastocytosis: Concerning clinically approved drugs to treat CM, vemurafenib, dabrafenib, and encorafenib have proved to selectively inhibit activated BRAFV600E/K/R/D monomers (class I BRAF mutants) in CM cancer cells, with an initial promising clinical success and wide therapeutic index [16].